Ginaton
Phase 3Small molecule
Ginaton is one of 84 small molecule programs targeting Hearing Loss. It is currently in Phase 3.
4
Indications
4
Total Trials
2
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Ozempic
Novo NordiskPhase 3
Reminyl
WWim Janssens
Phase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Aggrastat
MMedicure
Phase 3
Ginaton
PPeking University People's Hospital
Phase 3
Zastaprazan
YYonsei University
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke1 trial
Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke
Completed·—·N/A·NCT05169450·998 enrolled
Diabetic Retinopathy1 trial
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07236645·200 enrolled
ISS1 trial
The Effect of PAP on ISSHL Comorbided With OSA
Recruiting·—·Phase 4·NCT04192656·102 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ginaton. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details